$DNA

Discovered @alchemytoday over the weekend

He's a JHU PhD who is now a P.I. at ULisbon. Focuses on #singlecell microbiology🦠

He picked up on some *NOTABLE* details in 175 page short report released by 🦂 last week

Will curate his posts in this🧵

itqb.unl.pt/research/biolo…
On the possible psychology behind the design of the document (see formatting)

$DNA

More on the possible psychology behind the design of the document (see formatting)

$DNA

On the $SYBX revenue booking allegation and the primary source research presented in support of said allegation ("turns out out to be someone who doesn't remember [the] numbers")

$DNA

From another poster: on whether $DNA receiving $SYBX equity in exchange for granting Foundry constitutes "round-tripping"

It was disclosed at the time of the $SRNG SPAC announcement (see next post down)

Here @alchemytoday highlights the $SYBX $DNA equity deal adjustment clearly noted at the time of $SRNG SPAC announcement

On the DARPA overcharging allegation and the primary source research presented in support of said allegation

There is a distinction between a "statement of work" (scoping of project + terms/conditions for client to approve) and invoice (actual bill)

$DNA
More on the DARPA overcharging allegation and the primary source research presented in support of said allegation (see post directly above)

$DNA

On why $DNA booked deferred revenue (NOT actual rev) for Kalo weeks after co was formed

Answer: it has contract consisting of "10 material rights to future technical [R&D] services and commercial licenses"

Also a prediction: Kalo gives update soon

On text of "Disclosures" section on page 2

Says paid interviews "may be paraphrased, truncated and/or summarized solely at our discretion, and do not always represent a precise transcript... We have not conducted any diligence or other verification"

$DNA
On the ability to shift from "short" to "long" at any time

$DNA

More again on the possible psychology behind the design of the document (see formatting)

$DNA

On the three fold range of success rates from one paid expert

$DNA

^ Early AM Typo: should be single molecule microbiology. (All microbes are by definition single cell)

Single molecule refers to tracking individual RNA and proteins in cells with fluorescence

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Varro Analytics

Varro Analytics Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @Varro_Analytics

11 Apr
DISCUSSION THREAD

Topic: $SRNGU/ $SRNG and potential Ginkgo Bioworks SPAC deal. Specifically, $20B valuation mentioned by Bloomberg

Will walk through some mkt data on chart below

Comments encouraged

#SynBio
$ZY
$AMRS $CDXS $ABCL $SYBX $PGEN
$BLI $TWST $TXG
$WUXAY $CRL $PPD
^Will preface this w list of most interesting things in $SRNGU/ $SRNG S-1

1). HUGE cash trust: $1.5B

2). Mostly entertainment experts (they SPAC'd DraftKings), but sector agnostic

3). Criteria: "High growth +FCF potential"

2). One bio link: $ALLO $KRON @Vida_Ventures @bt_prop
Let's also establish

i). Ginkgo is IP creation biz (a #synbio $TXN/ $INTC/ $AMD) housed in automated CRO (see $PPD $WUXAY $CRL) "on steroids." That gets paid in cash+ stock/royalties

ii). Biology inherently hard to scale, but part of revenue magic of Ginkgo is code reuseability
Read 23 tweets
24 Mar
S-1 thread

@Zymergen( $ZY) surprised today w $100M Initial Public Offering. JPM, GS, BOA, Cowen

Last valued $1.75B

Word counts

"biofactur-": 173
Hyaline:140
"Nature" (capital N):39
#SyntheticBiology/#SynBio:26
#MachineLearning:24
@Amyris ( $AMRS):2
@Ginkgo:0
@Intrexon (RIP):0 Image
S-1 bit.ly/31b1qhl

$13M in R&D/collab revenue in 2020

$ZY spent "5 years & $50 million" to "launch" (w/o product rev) lead product Hyaline (electronic screen film)

Early version made w chem synthesis, NOT fermentation (#synbio), but plans to ferment later (lower COGS) ImageImageImageImage
^Hyaline chem synth underscores challenge of $ZY's biz model

$ZY trying to simultaneously design/build/test organisms AND market end products

Chem synth gets products into customer hands earlier than $XON/ $AMRS, but might improve top-line focusing on design/build/test w JV's Image
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(